BRPI0915367B8 - peptídeo anti-p2x7 - Google Patents

peptídeo anti-p2x7

Info

Publication number
BRPI0915367B8
BRPI0915367B8 BRPI0915367A BRPI0915367A BRPI0915367B8 BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8 BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8
Authority
BR
Brazil
Prior art keywords
peptides
antibodies
epitope
cancer
peptide
Prior art date
Application number
BRPI0915367A
Other languages
English (en)
Portuguese (pt)
Inventor
Gidley-Baird Angus
Alexander Barden Julian
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Publication of BRPI0915367A2 publication Critical patent/BRPI0915367A2/pt
Publication of BRPI0915367B1 publication Critical patent/BRPI0915367B1/pt
Publication of BRPI0915367B8 publication Critical patent/BRPI0915367B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915367A 2008-07-04 2009-07-03 peptídeo anti-p2x7 BRPI0915367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451 2008-07-04
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (3)

Publication Number Publication Date
BRPI0915367A2 BRPI0915367A2 (pt) 2015-11-03
BRPI0915367B1 BRPI0915367B1 (pt) 2020-10-13
BRPI0915367B8 true BRPI0915367B8 (pt) 2021-05-25

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915367A BRPI0915367B8 (pt) 2008-07-04 2009-07-03 peptídeo anti-p2x7

Country Status (12)

Country Link
US (3) US8597643B2 (cg-RX-API-DMAC7.html)
EP (1) EP2318438B1 (cg-RX-API-DMAC7.html)
JP (2) JP5701752B2 (cg-RX-API-DMAC7.html)
KR (1) KR101701300B1 (cg-RX-API-DMAC7.html)
CN (1) CN102143978B (cg-RX-API-DMAC7.html)
AU (1) AU2009266430B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915367B8 (cg-RX-API-DMAC7.html)
CA (1) CA2729868C (cg-RX-API-DMAC7.html)
ES (1) ES2610225T3 (cg-RX-API-DMAC7.html)
IL (2) IL210220A (cg-RX-API-DMAC7.html)
NZ (1) NZ590146A (cg-RX-API-DMAC7.html)
WO (1) WO2010000041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2009266430B2 (en) 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy
EP3277726A4 (en) * 2015-04-02 2018-08-22 Biosceptre UK Limited Pain treatment
WO2017041143A1 (en) 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof
CN109862883A (zh) 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
EP4319793A4 (en) * 2021-04-08 2025-03-19 Biosceptre (Aust) Pty Ltd Methods for controlling immune cell activity
EP4587465A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
WO2024055075A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells
AU2023343787A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
ES2329851T3 (es) * 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
WO2002047306A1 (en) * 2000-12-06 2002-06-13 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
CN100497386C (zh) * 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
PT1473367E (pt) 2003-04-17 2007-09-10 Affectis Pharmaceuticals Ag Meios e processos para o diagnóstico e tratamento de distúrbios afectivos
US20090215727A1 (en) * 2005-05-05 2009-08-27 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
AU2008299594B2 (en) * 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2009266430B2 (en) 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
ES2904911T3 (es) * 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
NZ590146A (en) 2012-09-28
IL232394A (en) 2016-04-21
CA2729868C (en) 2018-07-10
KR101701300B1 (ko) 2017-02-01
US20160199442A1 (en) 2016-07-14
EP2318438A1 (en) 2011-05-11
US9328155B2 (en) 2016-05-03
WO2010000041A1 (en) 2010-01-07
AU2009266430A1 (en) 2010-01-07
US20140135475A1 (en) 2014-05-15
IL232394A0 (en) 2014-06-30
US10238716B2 (en) 2019-03-26
JP2011526249A (ja) 2011-10-06
AU2009266430B2 (en) 2014-08-14
US8597643B2 (en) 2013-12-03
EP2318438A4 (en) 2012-11-21
CA2729868A1 (en) 2010-01-07
BRPI0915367B1 (pt) 2020-10-13
IL210220A (en) 2016-04-21
BRPI0915367A2 (pt) 2015-11-03
EP2318438B1 (en) 2016-11-02
CN102143978B (zh) 2015-02-18
CN102143978A (zh) 2011-08-03
JP2015038144A (ja) 2015-02-26
ES2610225T3 (es) 2017-04-26
IL210220A0 (en) 2011-03-31
AU2009266430A8 (en) 2011-03-10
JP5701752B2 (ja) 2015-04-15
KR20110031222A (ko) 2011-03-24
US20110110959A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
BRPI0915367B8 (pt) peptídeo anti-p2x7
ES2560532T3 (es) Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BRPI0908496A2 (pt) inibição de angiogênese
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
CL2014001297A1 (es) Anticuerpo multivalente que tiene al menos dos dominios de unión a receptores para dos diferentes sitios de unión de un receptor diana lrp6; anticuerpo aislado biparatopico que une lrp6; anticuerpo igg biparatópico; secuencia nucleotídica que los codifica; vector; composición farmacéutica que los comprende; y uso para tratar cáncer que exprese lrp6 (div. sol. n°3093-12).
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
CO6630173A2 (es) Moléculas de unión a seroalbuminae
GT201200271A (es) Proteínas que se unen al tnf-a
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CR20130609A (es) Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase 1
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
UA113712C2 (xx) Антитіло до fap і способи його застосування
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
WO2014134561A3 (en) Quantification of vaccine compositions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF